Abstract
The purpose of this Statement is to supplement previous conjugate meningococcal vaccine statements(1)-(4) which have outlined the use of monovalent meningococcal C and quadrivalent conjugate meningococcal vaccines. This statement will:
- Review existing NACI recommendations on the use of conjugate meningococcal vaccines;
- Update the epidemiology of meningococcal disease in Canada;
- Review and update information on quadrivalent conjugate meningococcal vaccines and vaccination schedules used in Canada following the approval of a new quadrivalent conjugate meningococcal vaccine Nimenrix™ (GlaxoSmithKline [GSK]) and of a new age indication for Menactra® (Sanofi Pasteur).
- Recommendation
- Americas
- Canada
- Meningococcal disease